Jiangsu Hengrui Medicine
600276.SS
#388
Rank
$58.63 B
Marketcap
$8.83
Share price
1.36%
Change (1 day)
30.49%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

Earnings for Jiangsu Hengrui Medicine (600276.SS)

Earnings in 2025 (TTM): $1.17 Billion USD

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current earnings are $4.19 Billion USD. In 2024 the company made an earning of $0.99 Billion USD, an increase over its 2023 earnings that were of $0.66 Billion USD. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Jiangsu Hengrui Medicine from 2002 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) $1.17 B18.6%
2024 $0.99 B50.59%
2023 $0.66 B11.35%
2022 $0.59 B-13.82%
2021 $0.68 B-34.16%
2020 $1.04 B16.28%
2019 $0.89 B32.92%
2018 $0.67 B20.82%
2017 $0.55 B23.8%
2016 $0.45 B11.25%
2015 $0.40 B39.52%
2014 $0.29 B20.71%
2013 $0.24 B11.46%
2012 $0.21 B29.6%
2011 $0.16 B31.28%
2010 $0.12 B27.89%
2009 $99.45 M5.84%
2008 $93.97 M79.89%
2007 $52.23 M32.93%
2006 $39.29 M38.14%
2005 $28.44 M21.56%
2004 $23.4 M13.95%
2003 $20.53 M38.06%
2002 $14.87 M